SCHEMBL5542221

SCHEMBL5542221

COc1cccc(CN[CH]c2ccccc2)c1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HIF1A Q16665 1/20 0.50
BCHE P06276 3/20 0.49
ACHE P22303 2/20 0.49
BACE1 P56817 2/20 0.49
ATM Q13315 1/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
TSHR P16473 1/20 0.49
CRHBP P24387 1/20 0.49
MAPK1 P28482 1/20 0.49
CRHR2 Q13324 1/20 0.49
NFE2L2 Q16236 1/20 0.49
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545752 0.87 ALDH1A1 (0.54) KMT2AMEN1KDM4EALDH1A1L3MBTL1
SCHEMBL5542256 0.81 HIF1A (0.46) KMT2AMEN1ALDH1A1L3MBTL1HIF1A
SCHEMBL4886662 0.80 KMT2A (0.55) KMT2AMEN1KDM4EALDH1A1L3MBTL1
SCHEMBL7000552 0.77 KDM4E (0.69) KMT2AMEN1KDM4EALDH1A1L3MBTL1
SCHEMBL29875218 0.75 ALDH1A1 (0.58) KMT2AMEN1KDM4EALDH1A1L3MBTL1
SCHEMBL680393 0.75 ALDH1A1 (0.58) KMT2AMEN1KDM4EALDH1A1L3MBTL1
SCHEMBL8879501 0.75 BCHE (0.78) KMT2AMEN1KDM4EALDH1A1L3MBTL1
SCHEMBL5543280 0.75 APLNR (0.59) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL5540592 0.75 MEN1 (0.53) KMT2AMEN1HIF1APOLBCYP1A2
SCHEMBL5546612 0.74 TACR1 (0.43) KMT2AMEN1KDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMT2A 4267/4885MEN1 3295/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.